ÆTERNA ZENTARIS

In Pursuit of Medical Innovations

FINANCIAL SNAPSHOT	
NASDAQ/TSX:	AEZS
SHARE PRICE:[1]	$4.01
MARKET CAP:[1]	~$20M
SHARES OUTSTANDING:[2]	~4.9M

Investor and Media Relations
JTC Team
+1 (833).475.8247
aezs@jtcir.com

[1] Based on November 4, 2022 closing price of $4.01 per share on NASDAQ and the number of issued and outstanding AEZS shares on that date, [2] Information as of September 30, 2022

Investment Highlights

Specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products

- Executing on strategy to rapidly advance lead programs through key milestones
- Strong financial position with runway expected to fund operations beyond 2023[1]

Therapeutics | Diagnostics | Vaccines

1: Based on Management's current expectations and planned development activities

Commercial and Development Pipeline

	Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial
Therapeutics	AIM Biologicals	Parkinson's Disease (PD)		Presented positive preclinical results at IMMUNOLOGY2022™			
		Neuromyelitis Optica Spectrum Disorder (NMOSD)		Positive PoC data presented at 13th Intl. Congress on Autoimmunity (Athens, June 2022)			
	Macimorelin	Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease)		Proof-of-concept studies in ALS disease models ongoing; formalized preclinical tox and safety testing initiated			
	AEZS-150 (Delayed clearance parathyroid hormone)	Chronic Hypoparathyroidism		Development of manufacturing process and *in-vivo* testing of development candidate processing			
Vaccine	Salmonella-Based Vaccine Platform	Covid-19 (SARS-CoV-2)		Immunization studies ongoing			
		Chlamydia Trachomatis		Optimization of candidate strains ongoing; establishment of challenge model initiated			
Diagnostics	Macimorelin	Adult Growth Hormone Deficiency (AGHD)					
	Macimorelin	Childhood-Onset Growth Hormone Deficiency (CGHD)					

Pivotal Phase 3 DETECT[1] Study for Diagnosis of CGHD

Currently Enrolling Subjects and Dosing is Underway

- **Open-label, single dose, multicenter, multinational**
  US, Germany, Poland, Georgia, Italy, Serbia, Romania and Slovenia
- **Macimorelin GHST will be performed twice (for repeatability data)**
- **Two standard GHSTs as controls: arginine (i.v.), clonidine (p.o.)**
- **Design suitable to support claim for potential of macimorelin as stand-alone test**
- **The impact of delays due to the COVID-19 pandemic and the Russian invasion of Ukraine – two countries where we planned to recruit patients – will extend the recruitment phase into H2 2023.**
- **Mitigation activities ongoing aiming at additional countries**

Children and adolescents from 2 to less than 18 years of age with suspected GHD to be enrolled

2 (Years) <18

≥ 100 subjects worldwide

≥ 40 pre-pubertal and 40 pubertal subjects

≥ 25 subjects expected to be enrolled in the U.S.

1: NCT 04786873 ClinicalTrials.gov

Macimorelin Commercial Rights

Actively seeking commercial partners in ROW

U.S. / Canada

Novo Nordisk
- Commercial and co-development agreement
- Funding 100% of budgeted DETECT study up to €9 million
- Returning full rights to Macrilen™(Macimorelin) in U.S. and Canada to Aeterna Zentaris in May 2023

Aeterna Zentaris
- Robust business development efforts to identify and secure a new development and commercialization partner

Consilient Health License Agreement

- Territories: Europe and the United Kingdom
- Pricing and reimbursement milestones
- Royalties on sales
- Aeterna Zentaris controls supply chain and provides finished product according to supply agreement

License Agreement on Development and Commercialization

Pharmbio Korea Inc.

In Republic of Korea

Distribution and Commercialization Agreement

MegaPharm We Know The Way

In Israel and the Palestine Authority

Distribution and Commercialization Agreement

ER·KIM

In Turkey and some Balkan countries

Aeterna Zentaris Owns Worldwide Rights Outside Europe, Israel and the Palestine Authority